JP2025508690A5 - - Google Patents

Info

Publication number
JP2025508690A5
JP2025508690A5 JP2024547005A JP2024547005A JP2025508690A5 JP 2025508690 A5 JP2025508690 A5 JP 2025508690A5 JP 2024547005 A JP2024547005 A JP 2024547005A JP 2024547005 A JP2024547005 A JP 2024547005A JP 2025508690 A5 JP2025508690 A5 JP 2025508690A5
Authority
JP
Japan
Prior art keywords
seq
cdr
functionally linked
variable region
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062151 external-priority patent/WO2023150797A2/en
Publication of JP2025508690A publication Critical patent/JP2025508690A/ja
Publication of JP2025508690A5 publication Critical patent/JP2025508690A5/ja
Pending legal-status Critical Current

Links

JP2024547005A 2022-02-07 2023-02-07 癌免疫療法のためのａｒｔ１の標的化 Pending JP2025508690A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307502P 2022-02-07 2022-02-07
US63/307,502 2022-02-07
PCT/US2023/062151 WO2023150797A2 (en) 2022-02-07 2023-02-07 Targeting art1 for cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2025508690A JP2025508690A (ja) 2025-04-10
JP2025508690A5 true JP2025508690A5 (enExample) 2026-02-16

Family

ID=87553072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547005A Pending JP2025508690A (ja) 2022-02-07 2023-02-07 癌免疫療法のためのａｒｔ１の標的化

Country Status (6)

Country Link
US (1) US20250382381A1 (enExample)
EP (1) EP4476266A4 (enExample)
JP (1) JP2025508690A (enExample)
AU (1) AU2023216372A1 (enExample)
CA (1) CA3251163A1 (enExample)
WO (1) WO2023150797A2 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497783A3 (en) * 2007-09-26 2013-04-17 U3 Pharma GmbH Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
WO2014078373A1 (en) * 2012-11-13 2014-05-22 Iogenetics, Llc Antimicrobial compositions
JP6683598B2 (ja) * 2013-03-15 2020-04-22 マックスサイト インコーポレーティッド 安定なトランスフェクトされた細胞を生成するための方法および組成物
WO2021204781A1 (en) * 2020-04-06 2021-10-14 Universität Zürich Artc1 ligands for cancer treatment

Similar Documents

Publication Publication Date Title
Wang et al. Silencing Fc domains in T cell–engaging bispecific antibodies improves T-cell trafficking and antitumor potency
CN116396386A (zh) Cd3抗体及其药物用途
KR102627471B1 (ko) 조작된 항-il-2 항체
JP2023524149A (ja) Ｃｄ３およびｃｄ２０に対する二重特異性抗体
JP2022528067A5 (enExample)
US12460002B2 (en) CD3 binding molecules
WO2021003739A1 (zh) 四价对称双特异性抗体
JP7717687B2 (ja) 腎疾患における抗幹細胞因子抗体及びその使用方法
JP2024509501A5 (enExample)
TW202317636A (zh) 靶向egfr及her3的雙特異性四價抗體
CN108138169A (zh) 抗Eva1蛋白质抗体
CN118339187A (zh) 抗pd-1抗体及其用途
CN118591565A (zh) 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途
JP2024522075A5 (enExample)
JP2025508690A5 (enExample)
WO2023222135A1 (en) A method of treating solid tumor
KR20250169618A (ko) Cd3 및 cd20에 대한 이중특이적 항체를 사용하여 림프종을 치료하는 방법
WO2023221935A1 (zh) 结合pd-l1和cldn18.2的抗体及其用途
JP2024508597A5 (enExample)
JP6974500B2 (ja) ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法
WO2023227115A1 (en) A method of treating solid tumor
EP4660204A1 (en) Antagonist for use in treatment of membranous nephropathy
US20250223361A1 (en) Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
JP2020533278A (ja) Ｋ−Ｒａｓ遺伝子の状態に関連したＣＫ８陽性がんの治療
US11518811B2 (en) Human antibody and fragments thereof for use in the treatment of gastric cancer (GC) and other types of tumours expressing the MICA protein (MHC class I chain-related protein A gene)